- Home
- TIXT vs AVBP Comparison
TIXT vs AVBP Comparison
Compare TIXT & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIXT
- AVBP
- Stock Information
- Founded
- TIXT 2005
- AVBP 2021
- Country
- TIXT Canada
- AVBP United States
- Employees
- TIXT N/A
- AVBP N/A
- Industry
- TIXT EDP Services
- AVBP
- Sector
- TIXT Technology
- AVBP
- Exchange
- TIXT Nasdaq
- AVBP NYSE
- Market Cap
- TIXT 1.0B
- AVBP 948.5M
- IPO Year
- TIXT 2021
- AVBP 2024
- Fundamental
- Price
- TIXT $4.01
- AVBP $27.10
- Analyst Decision
- TIXT Hold
- AVBP Strong Buy
- Analyst Count
- TIXT 9
- AVBP 5
- Target Price
- TIXT $5.78
- AVBP $36.80
- AVG Volume (30 Days)
- TIXT 479.4K
- AVBP 148.6K
- Earning Date
- TIXT 02-07-2025
- AVBP 02-02-2025
- Dividend Yield
- TIXT N/A
- AVBP N/A
- EPS Growth
- TIXT N/A
- AVBP N/A
- EPS
- TIXT N/A
- AVBP N/A
- Revenue
- TIXT $2,659,000,000.00
- AVBP N/A
- Revenue This Year
- TIXT N/A
- AVBP N/A
- Revenue Next Year
- TIXT $2.16
- AVBP N/A
- P/E Ratio
- TIXT N/A
- AVBP N/A
- Revenue Growth
- TIXT 0.49
- AVBP N/A
- 52 Week Low
- TIXT $2.83
- AVBP $14.35
- 52 Week High
- TIXT $11.51
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- TIXT 59.06
- AVBP 47.58
- Support Level
- TIXT $3.60
- AVBP $26.36
- Resistance Level
- TIXT $3.92
- AVBP $27.67
- Average True Range (ATR)
- TIXT 0.19
- AVBP 1.20
- MACD
- TIXT 0.03
- AVBP 0.13
- Stochastic Oscillator
- TIXT 85.27
- AVBP 78.34
About TIXT TELUS International (Cda) Inc. Subordinate Voting Shares
TELUS International (Cda) Inc is a digital customer experience innovator that designs, builds, and delivers next-generation solutions. Its clients include companies across several verticals, including Tech and Games, eCommerce and FinTech, Banking, Financial Services and Insurance, Communications and Media, and Healthcare. The solutions offered by the company include Digital Experience, Customer Experience, Advisory Services, and Back Office and Automation among other services. Geographically, it derives a majority of its revenue from the European region.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.